curcumin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Conversely, MDA levels, a marker of lipid peroxidation, were significantly lower in the curcumin group compared with placebo (1.29 [1.05–1.58] vs. 2.45 [2.14–2.77], p < 0.001), corresponding to a large effect size ( r = 0.85, 95% CI: 0.77–0.91).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry fundedPermalink
Keep reading
- Everything the graph holds on curcumin
- Every compound studied against Malondialdehyde (circulating)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M0Q1MWANZ415VK9TZHZXKHT9